Dr. Karthikeyan Kandavelou, MD

Dr. Kandavelou practices at Connecticut Oncology Group PC - HOPD in Middletown, Connecticut.

Dr. Kandavelou's NPI, 1730316068, was assigned on June 12, 2009. Dr. Kandavelou holds Connecticut license 53842.

Dr. Kandavelou's primary practice is Connecticut Oncology Group PC - HOPD, at 536 Saybrook Rd, Middletown, CT 06457.

Dr. Kandavelou's primary practice is Connecticut Oncology Group PC - HOPD in Middletown, Connecticut. Dr. Kandavelou is also affiliated with Middlesex Hospital. The medical group on file is Connecticut Oncology Group. Dmand AI also links Dr. Kandavelou to 1 more group practice or clinic and 1 hospice, each named with a free account. Dr. Kandavelou's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kandavelou practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kandavelou's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kandavelou is licensed in Connecticut.

CMS data shows 76,393 Medicare services from Dr. Kandavelou across 26 procedure codes in 2024, for 361 Medicare patients. Medicare paid $280,496 for them. Every service was in an office.

CMS counts 361 Medicare patients who saw Dr. Kandavelou in 2024. The largest group is 75 to 84, with 147 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kandavelou's median patient age at 72, with 48% women.

In 2024, Dr. Kandavelou wrote 1,173 Medicare Part D claims for 186 patients. 75% of them were for generic drugs. CMS names the drug for 1,002 of them, across 32 drugs with 11 or more claims each, at $2,896,443 in total drug cost. In 2023, CMS named 901 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kandavelou for performance year 2024, reported as part of a group. Dr. Kandavelou accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Kandavelou in 2012. 2012 was the busiest year, with 2. The most frequent topics are Fibroblasts, Genetic Engineering and Induced Pluripotent Stem Cells. Dr. Kandavelou's most frequent co-author is Lionel S. Lim, MD.

CMS Open Payments shows 55 general payments to Dr. Kandavelou from 21 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 76% of the total. Genentech, Inc. paid the most, $177.